ACORDA - Building Confidence Beyond AMPYRA!
Acorda Therapeutics (ACOR) reported 4Q/FY12 results with a decent growth in sales of marketed products and promises to strengthen its pipeline and focus on unmet needs in CNS diseases. Growth in AMPYRA’s Sales reflects ACOR’s concerted marketing efforts which have helped improve awareness amongst physicians and pts. Potential label expansion of AMPYRA (POC data in 2Q13) and pipeline beyond AMPYRA could lead to the next driver to the stock. Successful development of AMPYRA, as well as additional pipeline products makes ACOR an attractive target for………. For more details, please read our report released on 15th February 2013 on ACOR titled “Building Confidence Beyond AMPYRA!”
